sutthirat sutthisumdang Shares of Aclaris Therapeutics ( NASDAQ: ACRS ) rallied 53% Monday after the company announced it had exclusively licensed two immunology drug candidates from Biosion, prompting an upgrade by Piper Sandler. Early Monday, Aclaris ( ACRS ) said it had entered into an exclusive.
Back to Health Page
